Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Molecular Oncology
|
September 19, 2019
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Sergio Villatoro, Clara Mayo-de-Las-Casas, Núria Jordana-Ariza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer
Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 26, 2022
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Carlos Aguado de la Rosa, Patricia Cruz Castellanos, Martín Lázaro-Quintela, et al.
Expert Opinion on Biological Therapy
|
May 20, 2026
Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
Mariano Provencio, David Aguiar, Mónica Antoñanzas, et al.
Thrombosis Research
|
November 17, 2023
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Inmaculada Aparicio, Patricia Iranzo, Roxana Reyes, et al.
JAMA Oncology
|
July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.
Molecular Cancer
|
July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
The New England Journal of Medicine
|
June 28, 2023
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
Mariano Provencio, Ernest Nadal, José L González-Larriba, et al.
The Lancet. Respiratory Medicine
|
April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Molecular Oncology
|
September 19, 2019
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Sergio Villatoro, Clara Mayo-de-Las-Casas, Núria Jordana-Ariza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer
Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 26, 2022
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Carlos Aguado de la Rosa, Patricia Cruz Castellanos, Martín Lázaro-Quintela, et al.
Expert Opinion on Biological Therapy
|
May 20, 2026
Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
Mariano Provencio, David Aguiar, Mónica Antoñanzas, et al.
Thrombosis Research
|
November 17, 2023
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Inmaculada Aparicio, Patricia Iranzo, Roxana Reyes, et al.
JAMA Oncology
|
July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.
Molecular Cancer
|
July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
The New England Journal of Medicine
|
June 28, 2023
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
Mariano Provencio, Ernest Nadal, José L González-Larriba, et al.
The Lancet. Respiratory Medicine
|
April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Page
of 8